Menu

Carrageenan

Also known as: E407, Food-grade carrageenan

A red-seaweed food hydrocolloid whose texture role, molecular specifications and limited metabolic research need separate interpretation.

Monoprint study of branching red seaweed beside a translucent gel swatch
Editorial illustration

Carrageenan is a red-seaweed-derived hydrocolloid permitted for specified food-texture functions. It is not simply another name for degraded poligeenan. A small human study raised permeability and BMI-related metabolic questions, but did not find a significant overall insulin-sensitivity difference or establish that every carrageenan-containing food causes diabetes.1, 2, 3

  • The U.S. rule permits the amount necessary for an emulsifier, stabilizer or thickener, subject to its conditions.1
  • The 2024 crossover study enrolled 20 men; each intervention lasted two weeks.3
  • The 2018 EFSA opinion identified unresolved chemical, exposure and toxicological questions; its historical temporary ADI is not a recommended supplement dose.2

What is Carrageenan?

The U.S. rule defines a refined, aqueous-extracted sulfated polysaccharide. EFSA's 2018 final opinion separately discusses food-grade material, degraded preparations and low-molecular-weight fractions. Keeping those identities distinct is necessary without pretending that the specification uncertainties disappear.1, 2

Where it comes from

Natural sources

  • Hydrocolloid extracted from specified red seaweeds

How it's made

Refining, preparation and molecular-weight distribution matter; the natural source does not authenticate an unspecified powder or establish medicinal activity.

What it does in products

  • Food stabilization
  • Thickening and emulsification under defined food-use conditions

Benefits

A technical texture function, not established metabolic therapy

insufficient evidence

Food formulation use should not be presented as a supplement health benefit.1, 3

The cited human trial was a safety/mechanistic investigation, not treatment of diabetes or bowel disease. A permitted thickening function does not establish a beneficial clinical effect.

Evidence scope and limitations

U.S. food-grade identity and technical uses, the dated 2018 EFSA final opinion and one adult metabolic trial; not nasal medicines, every carrageenan subtype or a full clinical bowel-disease review.

  • Twenty men and two-week exposure periods cannot establish lifelong disease risk or generalize to all populations.
  • Overall endpoints and BMI-dependent findings are not interchangeable.
  • The older EFSA opinion is identified by date; its temporary benchmark is not represented as a newly resolved 2026 assessment.

Evidence last checked: 2026-10-16

Side effects & safety

A limited permeability and metabolic signal (varies)The short trial reported greater intestinal permeability and BMI-related findings. Its overall insulin-sensitivity comparison was not significant, and it cannot supply a long-term disease risk estimate.

Safety considerations

  • The selected experiment does not establish a complete interaction profile or the response to every mixed food matrix.
  • Not for: The all-male adult trial cannot settle infant or pregnancy exposure questions.
  • Not for: Neither food-grade permission nor a degraded-material experiment establishes safety or harm for every product or gastrointestinal condition.
2, 3

Amounts studied & product use

These figures describe research or common product use, not a personal dose or treatment recommendation.

In supplement studies and products

The study administered 250 mg twice daily for two-week periods; this is a research exposure, not a recommended regimen. Food use is a separate technical question governed by the quantity needed for the permitted function, not a home supplement target.

1, 3

Regulatory status

  • 21 CFR 172.620 sets U.S. identity and food-use conditions. EFSA's cited opinion is a 2018 European assessment with explicit uncertainties, not a claim of a new 2026 all-use clearance. Its distinction between carrageenan and unauthorized degraded poligeenan should not be erased.
1, 2

Avoid both shortcuts in the safety debate

Calling food-grade carrageenan poligeenan ignores a material distinction. Calling every molecular-weight question resolved because the source is seaweed ignores the final assessment's concerns. A credible comparison needs to identify the actual preparation.

Likewise, a BMI interaction and permeability finding in 20 men deserve follow-up, but are not a universal diabetes diagnosis. The interpretation should preserve both the signal and the nonsignificant overall endpoint.

2, 3

Frequently asked questions

Is carrageenan identical to poligeenan?

No. The final EFSA assessment distinguishes the authorized food additive from degraded preparations while also discussing uncertainty about lower-molecular-weight fractions.2

Did the 2024 trial show that carrageenan causes diabetes?

No. It measured short-term metabolic and permeability outcomes, not new diabetes cases. The overall insulin-sensitivity difference was not significant.3

The bottom line

Identify the grade and preparation, then distinguish technical food use from what a short metabolic experiment can actually establish.

References

  1. 21 CFR 172.620: Carrageenan. Electronic Code of Federal Regulations · government guidance · Current red-seaweed identity and technical food-use conditions checked October 16, 2026
  2. EFSA Panel on Food Additives and Nutrient Sources added to Food. Re-evaluation of carrageenan (E 407) and processed Eucheuma seaweed (E 407a) as food additives. EFSA Journal (2018) · safety assessment · DOI 10.2903/j.efsa.2018.5238; final opinion adopted March 14, published April 26, 2018; definitions, uncertainties and historical temporary ADI checked
  3. Wagner R, Buettner J, Heni M, et al.. Carrageenan and insulin resistance in humans: a randomised double-blind cross-over trial. BMC Medicine (2024) · randomized trial · PMID 39593091; DOI 10.1186/s12916-024-03771-8; NCT02629705; primary abstract checked; overall and BMI-interaction findings separated

Revision history

  1. Initial AI-assisted source checks and claim-level citation mapping under the site-authorized publishing workflow. No separate human or independent medical review is claimed.